שווי הפעילות העסקית: titanpharm.com (TTNP)

Titan Pharmaceuticals (TTNP) is developing an addiction therapy system through its proprietary ProNeura subcutaneous devices, creating a closed supply network. However, the business is burdened by litigation, a shortage of funds, and the low popularity of current systems. This price chart on GURU.Markets shows that the Enterprise Value is . The company is currently focused on the international licensing of its molecules and the maintenance of existing medical patents.

The enterprise value of Titan Pharmaceuticals (TTNP) combines market capitalization and debt obligations minus liquid assets, determining the actual cost of acquiring the business while accounting for the regulatory risks of drug delivery platforms. By analyzing the projected enterprise value, an investor can assess whether the current buyout price is justified by clinical trial successes and the company's ability to scale partner manufacturing to ensure financial stability.